June 24, 2025
Description:
The 2024 CDC MEC and SPR included a number of significant changes that clinicians should be aware of. In addition to new recommendations regarding people with chronic kidney disease, the 2024 MEC includes revised risk categories for some people using depot-medroxyprogesterone acetate (DMPA). The SPR has an expanded section of pain management for IUD placement and bleeding problems with implant use. The QFP Guidelines are an update of the 2014 QFP and contain state-of-the-art contraceptive counseling guidelines. The changes will be discussed in detail, as well as a review of the MEC/SPR app and job aids available from the CDC.
Learning Objectives:
- List the contraceptives that are considered to be Category 3 or 4 in people with chronic kidney disease.
- For people using DMPA, list three medical conditions that had changes in their U.S. MEC safety category.
- Describe two changes in the section of the SPR on bleeding irregularities during implant use.
Speakers:
Jennifer Karlin, MD, PhD
Associate Professor, Department of Family & Community Medicine, University of California, San Francisco School of Medicine
Project Principal Investigator, National Clinician Consultation Center, Medical Consultant for the CA Family PACT Program, California Prevention Training Center
Associate Editor, Annals of Family Medicine
Michael Policar, MD, MPH
Professor Emeritus, Department of Obstetrics, Gynecology & Reproductive Sciences, University of California, San Francisco School of Medicine
Clinical Fellow, National Family Planning and Reproductive Health Association (NFPRHA)
Resources: